Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer

americanpharmaceuticalreviewApril 14, 2021

Tag: LINDIS , Catumaxomab , NMIBC , cancer , Catunibla

PharmaSources Customer Service